The Federal Circuit affirmed the decision of the Patent Trial and Appeal Board that challenged claims of Merck Serono S.A.'s patents that relate to the treatment of multiple sclerosis are unpatentable as obvious over prior art, in inter partes reviews by TWi Pharmaceuticals Inc. The court affirmed the board’s prior art finding.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.